{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T15:50:49Z","timestamp":1775836249931,"version":"3.50.1"},"reference-count":33,"publisher":"Microbiology Society","issue":"4","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,10]]},"abstract":"<jats:p>\n                    <jats:bold>Introduction.<\/jats:bold>\n                    Clinical trials and observational studies of co-formulated regimens bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/F\/TAF) and doravirine\/lamivudine, tenofovir disoproxil fumarate (DOR\/3TC\/TDF) demonstrated potent efficacy in both antiretroviral therapy-naive and -experienced patients, but data on efficacy in naive people with high-level Human Immunodeficiency Virus (HIV) viraemia are still lacking.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Hypothesis.<\/jats:bold>\n                    BIC\/F\/TAF and DOR\/3TC\/TDF have comparable effectiveness in naive people with high-level viraemia.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Aim.<\/jats:bold>\n                    To compare the effectiveness of BIC\/F\/TAF and DOR\/3TC\/TDF in naive people with high-level viraemia.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methodology.<\/jats:bold>\n                    We performed a retrospective cohort study of adult people living with HIV, who were naive to antiretroviral therapy, had baseline HIV-1 RNA\n                    <jats:underline>&gt;<\/jats:underline>\n                    500,000 copies ml\n                    <jats:sup>\u22121<\/jats:sup>\n                    and initiated the co-formulated regimen BIC\/F\/TAF or DOR\/3TC\/TDF. Virological efficacy, changes in immunological parameters and safety profiles after 12\u2009months of treatment were evaluated.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results.<\/jats:bold>\n                    Inclusion criteria were met by 78\u2009patients: 43 in the BIC\/F\/TAF group and 35 in the DOR\/3TC\/TDF group. Baseline characteristics were similar in both groups: median age was 45.2\u2009years, median HIV RNA was 5.95 log\n                    <jats:sub>10<\/jats:sub>\n                    , median CD4 T lymphocyte count was 383\u2009cells mm\n                    <jats:sup>\u22123<\/jats:sup>\n                    and 22\u2009patients (28%) had HIV RNA &gt;10\n                    <jats:sup>6<\/jats:sup>\n                    copies ml\n                    <jats:sup>\u22121<\/jats:sup>\n                    . After 12\u2009months, virological efficacy was comparable: HIV RNA &lt;20 copies ml\n                    <jats:sup>\u22121<\/jats:sup>\n                    was obtained in 40\u2009patients (93%) in the BIC\/F\/TAF group and in 31 (89\u200a%) in the DOR\/3TC\/TDF group. The median increase in CD4 T lymphocyte count was comparable between groups (+139\u2009and +117\u2009cells mm\n                    <jats:sup>\u22123<\/jats:sup>\n                    , respectively), such as incidence of adverse events, while median increase in low-density lipoprotein cholesterol and weight gain was significantly greater in the BIC\/F\/TAF group (weight change, +1.64\u2009kg vs. +0.85\u2009kg;\n                    <jats:italic>P<\/jats:italic>\n                    =0.013).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion.<\/jats:bold>\n                    In this real-life cohort, BIC\/F\/TAF and DOR\/3TC\/TDF showed high and comparable virological efficacy in naive patients with baseline HIV RNA above 500,000 copies ml\n                    <jats:sup>\u22121<\/jats:sup>\n                    .\n                  <\/jats:p>","DOI":"10.1099\/jmm.0.002119","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T15:16:26Z","timestamp":1775834186000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparable efficacy of bictegravir\/emtricitabine\/tenofovir alafenamide and doravirine\/lamivudine\/tenofovir disoproxil fumarate in therapy-naive Human Immunodeficiency Virus adults with very high baseline viraemia"],"prefix":"10.1099","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1895-1504","authenticated-orcid":false,"given":"Leonardo","family":"Calza","sequence":"first","affiliation":[{"name":"Department of Medical and Surgical Sciences, Unit of Infectious Diseases, S.Orsola Hospital, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maddalena","family":"Giglia","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, Unit of Infectious Diseases, S.Orsola Hospital, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Rigamonti","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, Unit of Infectious Diseases, S.Orsola Hospital, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Zuppiroli","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, Unit of Infectious Diseases, S.Orsola Hospital, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Marzolla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella","family":"Bon","sequence":"additional","affiliation":[{"name":"Unit of Microbiology, S.Orsola Hospital, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierluigi","family":"Viale","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, Unit of Infectious Diseases, S.Orsola Hospital, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"345","reference":[{"key":"R1","article-title":"EACS Guidelines. Version 12.1","year":"2024"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32299-7"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30077-3"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32340-1"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30080-3"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30099-0"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy540"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa822"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30021-3"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30336-4"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(24)00031-6"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318230372e"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0144317"},{"key":"R14","first-page":"289","article-title":"Why are baseline HIV RNA levels 100,000 copies\/mL or greater associated with mortality after the initiation of antiretroviral therapy?","volume":"38","author":"Wood","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60936-7"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1745"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32830285fb"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000147521.34369.c9"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69155-1"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1310\/hct0903-152"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282f5556d"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1086\/590943"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32834d0c20"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32833ad933"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12004"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1186\/s40249-020-00700-8"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12959"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13265"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad219"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-022-00734-5"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.107016"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.107049"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2024.107164"}],"container-title":["Journal of Medical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jmm\/10.1099\/jmm.0.002119?crawler=true&mimetype=application\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T15:16:26Z","timestamp":1775834186000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jmm\/10.1099\/jmm.0.002119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,10]]}},"URL":"https:\/\/doi.org\/10.1099\/jmm.0.002119","relation":{},"ISSN":["0022-2615","1473-5644"],"issn-type":[{"value":"0022-2615","type":"print"},{"value":"1473-5644","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]}}}